These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 30367020

  • 21. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.
    Smith E, Al-Abadi E, Armon K, Bailey K, Ciurtin C, Davidson J, Gardner-Medwin J, Haslam K, Hawley D, Leahy A, Leone V, McErlane F, Mewar D, Modgil G, Moots R, Pilkington C, Ramanan A, Rangaraj S, Riley P, Sridhar A, Wilkinson N, Beresford MW, Hedrich CM.
    Lupus; 2019 Apr; 28(5):613-620. PubMed ID: 30871425
    [Abstract] [Full Text] [Related]

  • 22. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
    Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, Liu Z, Li L.
    Lupus; 2007 Apr; 16(9):707-12. PubMed ID: 17728363
    [Abstract] [Full Text] [Related]

  • 23. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R, Stojanović R, Novicić-Sasić D, Dimitrijević J, Pavlović S, Stojković D, Palić-Obradović D, Stevanović G, Prodanović S.
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [Abstract] [Full Text] [Related]

  • 24. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, Meroni P, Messa P, Sinico AR.
    Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
    [Abstract] [Full Text] [Related]

  • 25. Treatment for lupus nephritis.
    Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli GF, Webster AC.
    Cochrane Database Syst Rev; 2012 Dec 12; 12():CD002922. PubMed ID: 23235592
    [Abstract] [Full Text] [Related]

  • 26. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
    Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, Pan X, Yu H.
    Nephrol Dial Transplant; 2007 Jul 12; 22(7):1933-42. PubMed ID: 17405792
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials.
    Liu LL, Jiang Y, Wang LN, Yao L, Li ZL.
    Drugs; 2012 Jul 30; 72(11):1521-33. PubMed ID: 22818016
    [Abstract] [Full Text] [Related]

  • 28. Sequential therapies for proliferative lupus nephritis.
    Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D.
    N Engl J Med; 2004 Mar 04; 350(10):971-80. PubMed ID: 14999109
    [Abstract] [Full Text] [Related]

  • 29. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
    Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB.
    N Engl J Med; 2005 Nov 24; 353(21):2219-28. PubMed ID: 16306519
    [Abstract] [Full Text] [Related]

  • 30. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study.
    Laskari K, Mavragani CP, Tzioufas AG, Moutsopoulos HM.
    Arthritis Res Ther; 2010 Nov 24; 12(6):R208. PubMed ID: 21059275
    [Abstract] [Full Text] [Related]

  • 31. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.
    Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA, ALMS Group.
    Arthritis Rheum; 2010 Jan 24; 62(1):211-21. PubMed ID: 20039429
    [Abstract] [Full Text] [Related]

  • 32. Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis.
    Lenz O, Fornoni A, Contreras G.
    Drugs; 2005 Jan 24; 65(17):2429-36. PubMed ID: 16296869
    [Abstract] [Full Text] [Related]

  • 33. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
    Joo YB, Kang YM, Kim HA, Suh CH, Kim TJ, Park YW, Lee J, Lee JH, Yoo DH, Bae SC, Lee HS, Bang SY.
    Int J Rheum Dis; 2018 May 24; 21(5):1031-1039. PubMed ID: 29611341
    [Abstract] [Full Text] [Related]

  • 34. Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis.
    Tse KC, Tang CS, Lam MF, Yap DY, Chan TM.
    J Rheumatol; 2009 Jan 24; 36(1):76-81. PubMed ID: 19004041
    [Abstract] [Full Text] [Related]

  • 35. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
    Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D, Aspreva Lupus Management Study Group.
    J Am Soc Nephrol; 2009 May 24; 20(5):1103-12. PubMed ID: 19369404
    [Abstract] [Full Text] [Related]

  • 36. [Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil].
    Sixdorf U, Bauer H, Märker-Hermann E.
    Dtsch Med Wochenschr; 2006 Oct 13; 131(41):2266-9. PubMed ID: 17036267
    [Abstract] [Full Text] [Related]

  • 37. What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?
    Jones RB, Walsh M, Smith KG.
    Curr Opin Rheumatol; 2009 May 13; 21(3):256-61. PubMed ID: 19399995
    [Abstract] [Full Text] [Related]

  • 38. Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study.
    Onishi A, Sugiyama D, Tsuji G, Nakazawa T, Kogata Y, Tsuda K, Naka I, Nishimura K, Misaki K, Kurimoto C, Hayashi H, Kageyama G, Saegusa J, Sugimoto T, Kawano S, Kumagai S, Morinobu A.
    Mod Rheumatol; 2013 Jan 13; 23(1):89-96. PubMed ID: 22447557
    [Abstract] [Full Text] [Related]

  • 39. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis.
    Aragon E, Resontoc LP, Chan YH, Lau YW, Tan PH, Loh HL, Ng KH, Yap HK.
    Lupus; 2016 Apr 13; 25(4):399-406. PubMed ID: 26537422
    [Abstract] [Full Text] [Related]

  • 40. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
    Chan TM, Tse KC, Tang CS, Mok MY, Li FK, Hong Kong Nephrology Study Group.
    J Am Soc Nephrol; 2005 Apr 13; 16(4):1076-84. PubMed ID: 15728784
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.